65.6% Radiological Fusion Rate at Three Months
Published in the International Journal 'Spine Open'

CGBio announced on June 12 that the results of a comparative study on spinal fusion surgery involving its bone graft substitute 'Novosis' have been published in the international journal 'Spine Open'.


Product photo of Novosis. CGBio

Product photo of Novosis. CGBio

View original image

This retrospective cohort study was conducted by Professor Naresh Kumar's team at the National University Hospital in Singapore. It compared and analyzed the clinical and radiological outcomes of two rhBMP-2 formulations used in transforaminal lumbar interbody fusion (TLIF) on 45 patients with degenerative lumbar disease (a total of 89 segments). The comparison was between Novosis and Infuse®, a globally recognized rhBMP-2 formulation.


The results showed differences in bone fusion formation patterns at early postoperative stages. At three months, the Novosis group exhibited a radiological fusion rate of 65.6%, while the control group showed a rate of 10.5% (P<0.001). At six months, fusion was confirmed in all cases in the Novosis group, while the control group showed a rate of 43.9%. However, by 12 months, both groups demonstrated high fusion rates, and the difference was not statistically significant.


Some differences were also observed in postoperative recovery indicators. The mean duration of drain maintenance was 3.2 days in the Novosis group, which was shorter than the 5.1 days observed in the control group (P=0.011). The research team suggested that these outcomes may be related to the carrier structure and release characteristics of rhBMP-2.


Novosis is a bone graft substitute based on bone morphogenetic protein (rhBMP-2) that supports bone formation in procedures such as spinal fusion, promoting the growth of new bone at the surgical site. Notably, it features a carrier composed of bone-like material designed to enable the gradual release of the protein. The study suggested that the characteristics of this carrier may have contributed to the early bone formation process.


Hyun Seung Yoo, CEO of CGBio, stated, "This study is significant in that it demonstrates how carrier technology, beyond just the active ingredient, can influence clinical outcomes in rhBMP-2 products," adding, "We will continue to validate the efficacy and safety of Novosis through a wide range of clinical data."



Meanwhile, CGBio is working to expand the clinical application of its regenerative medicine-based product portfolio, including Novosis, in the orthopedic and spinal fields, with plans to further strengthen its evidence-based competitiveness in the global market.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing